secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0000950170-23-024549
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M
--------------------------------------------------------------------------------

- Stockholders' equity of $2.1M as of March 31, 2023 misses Nasdaq minimum $2.5M requirement.
- Company must submit a compliance plan to Nasdaq by July 10, 2023.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- Failure to regain compliance could lead to delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/0000950170-23-024549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017023024549/evok-20230524.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer